iBio, Inc. (IBIO)Healthcare | Biotechnology | San Diego, United States | NasdaqCM
0.78 USD
+0.00
(0.256%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
After hours: 0.81 +0.03 (3.475%) ⇧ (Oct. 15, 2026, 6:20 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 7:22 a.m. EDT
The immediate outlook is severely clouded by a relentless downward price trend over the last five consecutive years, culminating in a nearly 99.97% collapse from the observation window's start. While recent headlines suggest institutional interest and a private placement, the stock has traded below its book value for some time and is now trading at a fraction of its historical highs, indicating the market has priced in significant distress. The lack of any dividend history eliminates income potential entirely. Although analysts offer a 'strong buy' rating with a target price significantly higher than the current level, this appears to be a speculative bet on a turnaround rather than a reflection of current operational reality, given the negative revenue growth and massive operating losses. For a short-term trader, the momentum is overwhelmingly bearish, and for a long-term holder, the fundamental deterioration suggests avoiding the security until the business model proves sustainable again. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.079394 |
| AutoARIMA | 0.079395 |
| MSTL | 0.080720 |
| AutoTheta | 0.096690 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 15.49 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.182 |
| Excess Kurtosis | -1.25 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.564 |
| Revenue per Share | 0.001 |
| Market Cap | 38,888,376 |
| Forward P/E | -1.27 |
| Beta | 1.26 |
| Website | https://ibioinc.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.082352936 |
| Address1 | 11,750 Sorrento Valley Road |
| Address2 | Suite 200 |
| All Time High | 30,300.0 |
| All Time Low | 0.56 |
| Ask | 1.42 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 1,146,710 |
| Average Daily Volume3 Month | 740,550 |
| Average Volume | 740,550 |
| Average Volume10Days | 1,146,710 |
| Beta | 1.257 |
| Bid | 1.02 |
| Bid Size | 2 |
| Board Risk | 2 |
| Book Value | 1.539 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,798,675,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.7828 |
| Current Ratio | 7.852 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 0.8208 |
| Day Low | 0.75 |
| Debt To Equity | 2.564 |
| Display Name | iBio |
| Dividend Date | 1,528,675,200 |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,758,542,400 |
| Earnings Timestamp Start | 1,758,193,140 |
| Ebitda | -29,492,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 1.208 |
| Enterprise To Revenue | -356.299 |
| Enterprise Value | -35,629,896 |
| Eps Current Year | -0.37556 |
| Eps Forward | -0.614 |
| Eps Trailing Twelve Months | -0.32 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.2542 |
| Fifty Day Average Change | -0.47139996 |
| Fifty Day Average Change Percent | -0.37585708 |
| Fifty Two Week Change Percent | -8.235293 |
| Fifty Two Week High | 3.82 |
| Fifty Two Week High Change | -3.0372 |
| Fifty Two Week High Change Percent | -0.7950785 |
| Fifty Two Week Low | 0.73 |
| Fifty Two Week Low Change | 0.0528 |
| Fifty Two Week Low Change Percent | 0.07232876 |
| Fifty Two Week Range | 0.73 - 3.82 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,219,152,600,000 |
| Float Shares | 52,111,385 |
| Forward Eps | -0.614 |
| Forward P E | -1.2749186 |
| Free Cashflow | -13,621,375 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 23 |
| Fullday Change | 0.029200017 |
| Fullday Change Percent | 3.7397563 |
| Fullday Price | 0.81 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 1.0 |
| Gross Profits | 100,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01324 |
| Held Percent Institutions | 0.55401003 |
| Implied Shares Outstanding | 49,678,561 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,025-03-04 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,782,777,600 |
| Last Split Date | 1,701,216,000 |
| Last Split Factor | 1:20 |
| Long Business Summary | iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies. In addition, the company is developing, an antibody therapeutics to treat glioblastoma and other cancers by selectively killing EGFRvIII tumor cells without destroying healthy tissue; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California. |
| Long Name | iBio, Inc. |
| Market | us_market |
| Market Cap | 38,888,376 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_33000 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -33,044,000 |
| Next Fiscal Year End | 1,814,313,600 |
| Non Diluted Market Cap | 79,740,997 |
| Number Of Analyst Opinions | 9 |
| Open | 0.75 |
| Operating Cashflow | -23,218,000 |
| Operating Margins | -301.38 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 979 446 0027 |
| Post Market Change | 0.027199984 |
| Post Market Change Percent | 3.474704 |
| Post Market Price | 0.81 |
| Post Market Time | 1,792,102,835 |
| Previous Close | 0.7808 |
| Price Eps Current Year | -2.0843542 |
| Price Hint | 4 |
| Price To Book | 0.50864196 |
| Price To Sales Trailing12 Months | 388.88376 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.496 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.11111 |
| Region | US |
| Regular Market Change | 0.0020000339 |
| Regular Market Change Percent | 0.25615188 |
| Regular Market Day High | 0.8208 |
| Regular Market Day Low | 0.75 |
| Regular Market Day Range | 0.75 - 0.8208 |
| Regular Market Open | 0.75 |
| Regular Market Previous Close | 0.7808 |
| Regular Market Price | 0.7828 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 346,694 |
| Return On Assets | -0.30805 |
| Return On Equity | -0.65698 |
| Revenue Growth | -1.0 |
| Revenue Per Share | 0.001 |
| Sand P52 Week Change | 0.16440773 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 49,678,561 |
| Shares Percent Shares Out | 0.0653 |
| Shares Short | 4,202,419 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 5,204,475 |
| Short Name | iBio, Inc. |
| Short Percent Of Float | 0.0656 |
| Short Ratio | 6.9 |
| Source Interval | 15 |
| State | CA |
| Symbol | IBIO |
| Target High Price | 7.0 |
| Target Low Price | 4.2 |
| Target Mean Price | 5.68889 |
| Target Median Price | 6.0 |
| Total Cash | 88,039,000 |
| Total Cash Per Share | 1.369 |
| Total Debt | 2,198,000 |
| Total Revenue | 100,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.32 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.7785 |
| Two Hundred Day Average Change | -0.99569994 |
| Two Hundred Day Average Change Percent | -0.5598538 |
| Type Disp | Equity |
| Volume | 346,694 |
| Website | https://ibioinc.com |
| Zip | 92,121 |